Clinical Trial

Nintedanib for Improving Reproductive Outcomes in Adenomyosis

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the effectiveness and safety of nintedanib, an antifibrotic drug, in improving live birth rates for infertile women with adenomyosis who have frozen embryos. Based on promising animal data showing reduced uterine fibrosis, participants will be randomized to receive either standard progesterone therapy plus nintedanib or progesterone therapy alone for three months before undergoing a frozen embryo transfer cycle.
Trial Details
NCT Number NCT07162961
Lead Sponsor Sun Yat-sen University
Conditions Adenomyosis of Uterus
Enrollment 328 participants
Start Date 2025-09-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-09